Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | ESR1 | P03372 | 4/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | STS | P08842 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284331 | 1.00 | LMNA (0.67) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL1248414 | 0.89 | MAPT (0.66) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL4281651 | 0.89 | MAPT (0.66) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL7596856 | 0.87 | SMN1; SMN2 (0.53) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL5679838 | 0.86 | LMNA (0.64) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL5154685 | 0.86 | LMNA (0.64) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL1246984 | 0.86 | LMNA (0.64) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL5679791 | 0.86 | LMNA (0.64) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL5682148 | 0.86 | LMNA (0.64) | LMNASMN1; SMN2ESR1ADORA3ATM | |
| SCHEMBL8518252 | 0.85 | ESR1 (0.48) | LMNASMN1; SMN2ESR1ADORA3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278880-A1 | STEROID TREATMENT FOR HOT FLASHES | Pherin Pharmaceuticals, Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | PHERIN PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | claimed |
| WO-2009126825-A1 | STEROID TREATMENT FOR HOT FLASHES | PHERIN PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-1251856-B1 | METHOD OF INCREASING ALERTNESS BY ADMINISTRATION OF A VOMEROPHERIN, AND VOMEROPHERIN-EMITTING ALARM DEVICES | PHERIN PHARM INC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-0891188-A4 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | PHERIN PHARM INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-6544971-B1 | Alarm device especially for detecting fires, unauthorized entry or sleep apnea, or the presence of CO, CH4, propane or radon | PHERIN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | claimed |
| EP-1251856-A1 | METHOD OF INCREASING ALERTNESS BY ADMINISTRATION OF A VOMEROPHERIN, AND VOMEROPHERIN-EMITTING ALARM DEVICES | Pherin Pharmaceuticals, Inc. (US) | 2002-10-30 | — | — | EP | claimed |
| US-6331534-B1 | ADMINISTERING EFFECTIVE AMOUNT OF STEROID WITHIN NASAL PASSAGE OF INDIVIDUAL SUCH THAT IT BINDS SPECIFICALLY TO RECEPTORS ON SURFACE OF NASAL NEUROEPITHELIAL CELLS IN VOMERONASAL ORGAN | PHERIN PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | claimed |
| WO-2001056577-A1 | METHOD OF INCREASING ALERTNESS BY ADMINISTRATION OF A VOMEROPHERIN, AND VOMEROPHERIN-EMITTING ALARM DEVICES | PHERIN PHARMACEUTICALS, INC. (US) | 2001-08-09 | — | — | WO | claimed |
| EP-0715517-A4 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORP (US) | 2000-10-11 | — | — | EP | claimed |
| JP-2000504025-A | — | — | 2000-04-04 | — | — | JP | claimed |
| EP-0891188-A1 | STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH | Pherin Pharmaceuticals, Inc. (US) | 1999-01-20 | — | — | EP | claimed |
| US-5783571-A | SUBSTITUTED TETRAENE STEROIDS FOR CONTROLLING GLANDULAR FUNCTION | PHERIN CORPORATION (US) | 1998-07-21 | — | — | US | claimed |
| EP-0715517-A1 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1996-06-12 | — | — | EP | claimed |
| WO-1994028903-A1 | ESTRENE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1994-12-22 | — | — | WO | claimed |
| WO-2025217067-A1 | INTRANASAL DRUG DELIVERY SYSTEM | VISTAGEN THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | PHERIN PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-5272134-A | Fragrance compositions and other compositions which contain human pheromones | EROX CORPORATION (US) | 1993-12-21 | — | — | US | disclosed |
| WO-1993018742-A1 | FRAGRANCE COMPOSITIONS AND OTHER COMPOSITIONS WHICH CONTAIN HUMAN PHEROMONES | EROX CORPORATION (US) | 1993-09-30 | — | — | WO | disclosed |
| EP-0562843-A2 | Fragrance compositions and other compositions which contain human pheromones | EROX CORPORATION (US) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258040-A1 | STEROID TREATMENT FOR HOT FLASHES | CYP19A1, SHBG, HSD17B11 | LMNA 2321/4885SMN1; SMN2 3611/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.